SEO URLwww.firestrike.ai/deals/beyond-air-xtl-biopharmaceuticals-acquisition-2026-1
acquisitionAnnounced · Jan 14, 2026biotechnologySource · CredibleArticle · Factual
XTL Biopharmaceuticals acquires Beyond Air
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$32.5M
Target
Beyond Air
NASDAQ: XAIR · Garden City, New York
Acquirer
XTL Biopharmaceuticals
Full Acquisition
Status
Announced
XTL Biopharmaceuticals agreed to acquire Beyond Air. Reported deal value: $32.5M. Status: Announced. Sector: biotechnology. Target headquarters context: Garden City, New York, United States.
This page summarizes publicly available information about the transaction as of 2026-01-14. Figures and status may change as filings and press coverage update.
, a subsidiary of Beyond Air , Inc. , a biotechnology company pioneering disease-modifying therapeutics targeting the core pathophysiology of Autism Spectrum Disorder and neuro-oncology
Deal timeline
Announced
Jan 14, 2026 · biospace.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $32.5M. Figures and status may change as sources update.
Sources: biospace.com · Primary article · FireStrike proprietary index